InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,456.90
(
-0.14%
)
US TECH 100
19,005.79
(
-1.05%
)
Dow Jones
39,409.01
(
0.66%
)
Brent Oil
85.29
(
1.51%
)
Bitcoin
60,151.78
(
-4.76%
)
Post# of 647957
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Zorro

Send PM Follow Ignore
Followers 262
Posts 35002
Boards Moderated 3
Alias Born 02/22/2005

Zorro

Re: None

Sunday, 12/17/2023 3:13:55 PM

Sunday, December 17, 2023 3:13:55 PM

Post# of 647957
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
https://ih.advfn.com/stock-market/NASDAQ/arcutis-biotherapeutics-ARQT/stock-news/92826417/fda-approves-arcutis-zoryve-roflumilast-topical


"A fool and his money are soon parted.” ~Thomas Tusser

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up